Jazz Pharmaceuticals is planning an IPO designed to raise up to $172.5 million. Company execs evidently believe that their work in neurology and psychiatry will make their debut a positive one, even as other biotechs have run into stormy market seas. Morgan Stanley, Lehman Brothers, Credit Suisse, and Natexis Bleichroeder are handling the offering. The Palo Alto, CA-based developer launched a Phase III trial for its narcolepsy drug Xyrem as a treatment for fibromyalgia syndrome last fall.
- read the report in the IPO
ALSO: Akzo Nobel says that the IPO for Organon will proceed on March 27. Report